Healthcare ETFs to Buy as JNJ Slips 6% Despite Q3 Earnings Beat
Johnson & Johnson's Q3 earnings beat fails to prevent a 6% stock drop, but three healthcare ETFs offer diversified exposure to its growth potential.

What's Your Reaction?









